Saturday 17 October 2026
Export TCRT’s income statement to Excel — free account
Alaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.
2.63
0.45
+20.64%
Follow TCRT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 3 | — | — | — | — | 4 | 4 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(436.02) | (469.95) | (162.77) | (16.97) | (10.53) | — | — | 7.71 | (8.58) | (10.44) |
P/S ratio |
449.52 | 278.04 | 7.38 | 39.47 | 62.53 | — | — | 54.37 | 95.21 | 104.01 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(1,020.47) | (1,092.86) | (380.77) | (43.31) | (28.46) | — | — | (8.60) | (21.56) | (25.56) |
Beneish M-Score |
(4.88) | 0.41 | 33.64 | 1.65 | — | — | — | 3,935.29 | 5.85 | (7.33) |
P/Operating CF |
(11.40) | (5.17) | (2.92) | (19.18) | (15.46) | — | — | (22.72) | (50.04) | (54.62) |
P/B ratio |
2.92 | 1.48 | 3.42 | 3.55 | 4.03 | — | — | 3.14 | 0.00 | 0.00 |
Price to Tangible BV |
2.92 | 1.48 | 3.42 | 3.55 | 4.03 | — | — | 3.14 | 0.00 | 0.00 |
EV/Sales |
1,454.88 | 1,584.32 | 10.59 | 30.30 | 48.64 | — | — | 41.87 | 84.11 | 92.19 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(7.10) | (3.51) | (1.03) | (3.59) | (2.96) | — | — | (4.18) | (9.83) | (10.84) |
EV/FCF |
(13.92) | (4.81) | (1.08) | (3.57) | (2.81) | — | — | (4.14) | (9.70) | (10.74) |
Quick Ratio |
1.71 | 1.58 | 3.10 | 2.19 | 4.81 | 6.52 | 6.63 | 6.71 | 3.40 | 5.13 |
Current Ratio |
2.45 | 3.98 | 4.22 | 2.23 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 |
Net Debt/EBITDA |
0.33 | 0.23 | 0.20 | 1.16 | 0.70 | 1.39 | 1.35 | 1.16 | 1.34 | 0.49 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 25.82% | 25.42% | 3.29% | 2.16% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.43 | 0.42 | 0.04 | 0.02 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.05 |
Operating CF/Net income |
0.69 | 1.06 | 0.86 | 0.77 | 0.78 | 0.71 | 0.35 | (0.36) | 0.75 | 0.34 |
Capex/Depreciation |
(14.00) | 0.00 | 0.37 | (0.05) | (1.12) | (8.67) | (0.45) | (0.80) | (2.00) | (1.90) |
Interest Coverage |
— | — | (17.84) | (11.13) | (65.22) | — | — | — | — | — |
| (198.10%) | (111.80%) | (156.66%) | (78.11%) | (86.52%) | (73.04%) | (130.47%) | (2,441.67%) | 84.16% | (3,423.41%) | |
| (145.99%) | (84.93%) | (96.01%) | (47.22%) | (65.30%) | (62.61%) | (115.39%) | 136.80% | (69.13%) | (132.59%) | |
ROIC |
(343.83%) | (309.41%) | (8,741.58%) | (944.09%) | (791.83%) | (365.89%) | (205.22%) | (141.35%) | 0.00% | 0.00% |
Return on Tangible Assets |
(329.86%) | (226.81%) | (557.16%) | (99.05%) | (106.81%) | (65.31%) | (125.21%) | 180.83% | (102.98%) | (191.75%) |
Average Days of Receivables |
219.00 | 182.50 | 73.00 | 0.50 | 1,018.88 | 0.00 | 0.00 | 4,660.00 | 1.09 | 1.12 |
Research and Development Expense of Revenue |
27,260.00% | 3,620.00% | 325,580.00% | 856.19% | 12,473.12% | 0.00% | 0.00% | 23,379.45% | 705.65% | 2,299.83% |
Selling, General and Administrative Expense of Revenue |
57,340.00% | 44,600.00% | 244,380.00% | 449.76% | 6,925.63% | 0.00% | 0.00% | 13,642.47% | 231.62% | 209.55% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
8,280.00% | 4,350.00% | 56,000.00% | 120.74% | 2,707.04% | 0.00% | 0.00% | 5,160.27% | 132.32% | 123.19% |
Graham Net Nets |
0.19 | 0.67 | 0.29 | 0.20 | 0.18 | — | — | 0.28 | (0.18) | (0.11) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 439.38 | 629.09 |
Earnings Yield |
(68.42%) | (155.50%) | (169.49%) | (28.56%) | (33.93%) | — | — | (25.76%) | (12.16%) | (24.12%) |
Free Cash Flow Yield |
(23.25%) | (118.52%) | (133.31%) | (21.51%) | (27.71%) | — | — | (18.59%) | (9.11%) | (8.25%) |
Revenue per Share |
0.00 | 0.01 | 0.00 | 2.02 | 0.28 | 0.00 | 0.00 | 0.15 | 6.99 | 7.89 |
Operating CF per Share |
(1.47) | (3.10) | (18.84) | (20.19) | (42.98) | (40.77) | (36.47) | (51.67) | (59.85) | (67.06) |
Capex per Share |
(0.05) | 0.00 | 0.84 | (0.13) | (2.32) | (6.99) | (0.25) | (0.48) | (0.81) | (0.63) |
Free Cash Flow per Share |
(1.52) | (3.10) | (18.00) | (20.33) | (45.31) | (47.77) | (36.72) | (52.15) | (60.66) | (67.70) |
Cash per Share |
0.71 | 0.68 | 3.79 | 36.61 | 53.18 | 82.29 | 71.18 | 64.49 | 77.67 | 93.20 |
Shareholders Equity per Share |
1.11 | 1.29 | 3.94 | 26.64 | 40.60 | 88.67 | 84.82 | 89.39 | (105.98) | (88.88) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.11 | 1.29 | 3.94 | 26.64 | 40.60 | 88.67 | 84.82 | 89.39 | (105.98) | (88.88) |
Free Cash Flow |
(2.97) | (4.97) | (28.80) | (29.42) | (64.79) | (66.79) | (41.14) | (49.92) | (55.41) | (58.88) |
Working Capital |
1.18 | 2.06 | 6.31 | 29.63 | 62.79 | 112.22 | 92.97 | 74.80 | 69.93 | 89.08 |
Capital Expenditures |
(0.10) | — | 1.35 | (0.19) | (3.32) | (9.78) | (0.28) | (0.46) | (0.74) | (0.55) |
Net Current Asset Value |
1.18 | 2.06 | 6.31 | 27.42 | 42.02 | 108.23 | 91.39 | 74.80 | (111.63) | (78.76) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
19.60 | 0.00 | (269.20) | 0.07 | 8.35 | 0.00 | 0.00 | 3.14 | 0.12 | 0.08 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.08 | 0.00 | 1,827.00 | 0.44 | 0.27 | 0.11 | 0.57 | 0.52 | 0.30 | 0.34 |
Cash ROIC |
(83.86%) | (157.61%) | (232.81%) | (27.17%) | (40.95%) | (27.39%) | (23.23%) | (33.89%) | 214.25% | (1,567.94%) |
Accounts Receivable Turnover |
1.25 | 3.33 | 2.00 | 5.24 | 0.14 | 0.00 | 0.00 | 0.16 | 319.45 | 29.38 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.00 | 0.00 | 0.00 | 0.56 | 2.89 | 4.00 | 2.60 | 0.94 | 0.02 | 0.23 |
Average Payables |
0.56 | 0.57 | 1.00 | 1.38 | 1.16 | 0.93 | 0.81 | 2.56 | 2.29 | 1.08 |
Average Assets |
2.86 | 5.51 | 36.60 | 79.90 | 120.61 | 127.73 | 102.08 | 100.33 | 105.98 | 130.04 |
Average Common Equity |
2.11 | 4.19 | 22.43 | 48.31 | 91.02 | 109.50 | 90.29 | (5.62) | (87.05) | 5.04 |
Columns are period end dates